Breast Cancer

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD.

The risk of pain deterioration was similar with T-DXd/pertuzumab vs standard of care in the DESTINY-Breast09 trial.

Subgroup data from the phase 3 DESTINY-Breast05 trial further characterize the clinical benefit of T-DXd over T-DM1 in this breast cancer population.

Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.

Data from the ELEVATE trial may support elacestrant as an endocrine backbone in ER-positive, HER2-negative breast cancer.

A label for imlunestrant/abemaciclib in ER+/HER2– advanced breast cancer with ESR1 mutations will be sought.

Sunil Dutta, MD, discusses how whole-breast radiation or systemic therapy is responsible for controlling low-volume disease.

Atezolizumab plus neoadjuvant therapy was found to increase chemotherapy-induced ovarian failure among patients with TNBC.

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.

Results from the phase 3 DESTINY-Breast09 trial led to the approval of T-DXd plus pertuzumab in unresectable/metastatic HER2+ breast cancer.

The BOOG 13-08 trial shows omitting sentinel lymph node biopsy is noninferior to performing it in select older patients with early-stage, HR+ breast cancer.

“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.

Data from the EMBER-3 trial support imlunestrant alone or in combination with abemaciclib as a chemotherapy-free treatment option.

QOL improvements were observed among AYA breast cancer survivors after utilizing a mobile health intervention.

Data from the EPIK-B5 study support the use of alpelisib/fulvestrant in previously treated, HR-positive, HER2-negative, PIK3CA-mutated breast cancer.

Estrogen alone was associated with a lower risk of BRCA-mutated breast cancer, according to data from an ongoing study.

Real acupuncture vs sham acupuncture produced more meaningful cognitive outcomes among patients with breast cancer.

PRO data from the ASCENT-03 trial complement the meaningful PFS benefit observed with sacituzumab govitecan in advanced triple-negative breast cancer.

Data may support the strong oncologic outcomes of less invasive surgical options for patients with node-negative disease after neoadjuvant chemotherapy.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm vs 95.7% in the no MRI arm among patients with newly diagnosed breast cancer.

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

“HER2CLIMB-05 has demonstrated that the addition of tucatinib to HP represents an enhanced frontline maintenance therapy option for patients with HER2-positive metastatic breast cancer,” said Erika Hamilton, MD.

The primary end point of PFS was not statistically significant with sacituzumab govitecan vs chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Axillary dissection was more likely to be omitted among patients in the ALTERNATE trial when there was one positive sentinel node compared with 2 or more.